HomeCompareSHWGF vs JNJ

SHWGF vs JNJ: Dividend Comparison 2026

SHWGF yields 3.85% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHWGF wins by $85.8K in total portfolio value
10 years
SHWGF
SHWGF
● Live price
3.85%
Share price
$0.52
Annual div
$0.02
5Y div CAGR
38.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$116.0K
Annual income
$38,332.89
Full SHWGF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SHWGF vs JNJ

📍 SHWGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHWGFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHWGF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHWGF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHWGF
Annual income on $10K today (after 15% tax)
$326.92/yr
After 10yr DRIP, annual income (after tax)
$32,582.96/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SHWGF beats the other by $28,596.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHWGF + JNJ for your $10,000?

SHWGF: 50%JNJ: 50%
100% JNJ50/50100% SHWGF
Portfolio after 10yr
$73.2K
Annual income
$21,511.15/yr
Blended yield
29.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SHWGF
No analyst data
Altman Z
2.6
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHWGF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHWGFJNJ
Forward yield3.85%2.13%
Annual dividend / share$0.02$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.1%28%
Portfolio after 10y$116.0K$30.3K
Annual income after 10y$38,332.89$4,689.40
Total dividends collected$87.0K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHWGF vs JNJ ($10,000, DRIP)

YearSHWGF PortfolioSHWGF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,231$531.15$10,592$272.30+$639.00SHWGF
2$12,787$769.94$11,289$357.73+$1.5KSHWGF
3$14,814$1,131.40$12,123$472.89+$2.7KSHWGF
4$17,542$1,691.67$13,141$629.86+$4.4KSHWGF
5$21,356$2,585.53$14,408$846.81+$6.9KSHWGF
6$26,913$4,062.45$16,021$1,151.60+$10.9KSHWGF
7$35,405$6,607.64$18,122$1,588.22+$17.3KSHWGF
8$49,102$11,218.96$20,930$2,228.20+$28.2KSHWGF
9$72,621$20,081.68$24,792$3,191.91+$47.8KSHWGF
10$116,037$38,332.89$30,274$4,689.40+$85.8KSHWGF

SHWGF vs JNJ: Complete Analysis 2026

SHWGFStock

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.

Full SHWGF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SHWGF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHWGF vs SCHDSHWGF vs JEPISHWGF vs OSHWGF vs KOSHWGF vs MAINSHWGF vs ABBVSHWGF vs MRKSHWGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.